Barbieri B, Giuliani F C, Bordoni T, Casazza A M, Geroni C, Bellini O, Suarato A, Gioia B, Penco S, Arcamone F
Cancer Res. 1987 Aug 1;47(15):4001-6.
4'-Iodo-4'-deoxydoxorubicin is a doxorubicin (DXR) analogue with greater lipophilicity and reduced basicity of the amino group. In vitro 4'-iodo-4'-deoxydoxorubicin is more cytotoxic than DXR against a panel of human and murine cell lines and is characterized by a higher and faster uptake. In vivo, the spectrum of activity of 4'-iodo-4'-deoxydoxorubicin is comparable to that of DXR, but the new compound has higher activity against murine P388 leukemia resistant to DXR and against pulmonary metastases from Lewis lung carcinoma. Moreover, the new analogue exhibits antitumor activity also after p.o. administration and shows no cardiotoxicity in experimental systems.
4'-碘-4'-脱氧阿霉素是一种阿霉素(DXR)类似物,具有更高的亲脂性且氨基碱性降低。在体外,4'-碘-4'-脱氧阿霉素对一系列人和鼠细胞系的细胞毒性比DXR更强,其特点是摄取更高且更快。在体内,4'-碘-4'-脱氧阿霉素的活性谱与DXR相当,但这种新化合物对耐DXR的鼠P388白血病以及Lewis肺癌肺转移具有更高的活性。此外,这种新类似物口服给药后也表现出抗肿瘤活性,并且在实验系统中未显示出心脏毒性。